The impact of management option on out-of-pocket costs and perceived financial burden among men with localised prostate cancer in Australia within 6 months of diagnosis

Simple item page
dc.contributor.authorLindsay, Daniel
dc.contributor.authorNabukalu, Doreen
dc.contributor.authorRoberts, Matthew J.
dc.contributor.authorYaxley, John
dc.contributor.authorQuinn, Stephen
dc.contributor.authorRichards, Natalie
dc.contributor.authorFrydenbergK, Mark
dc.contributor.authorGardiner, Robert
dc.contributor.authorLawrentschuk, Nathan
dc.contributor.authorJuraskova, Ilona
dc.contributor.authorMurphy, Declan G.
dc.contributor.authorGordon, Louisa G.
dc.date.accessioned2025-05-20T11:58:23Z
dc.date.available2025-05-20T11:58:23Z
dc.date.issued2024
dc.description.abstractObjective This study aimed to quantify the out-of-pocket (OOP) costs and perceived financial burden among Australian men with localised prostate cancer in the first 6 months after diagnosis, by primary management option.Methods This cost-analysis quantified OOP costs using administrative claims data and self-reported survey data. Financial burden was assessed using the COmprehensive Score for financial Toxicity–Functional Assessment of Chronic Illness Therapy (COST-FACIT) tool. Participants were recruited into a randomised control trial from public or private treatment centres in Victoria and Queensland. Generalised linear models were used to predict OOP costs and COST-FACIT scores.Results Median total OOP costs within 6 months of diagnosis for 256 Australian patients with localised prostate cancer was A$1172 (A$343–2548). Up to 50% of the sample reported A$0 costs for most medical services. Compared with those managed with active surveillance, men having active treatment had 6.4 (95% CI: 3.2–12.7) times greater total OOP costs. Management option, higher Gleason score at diagnosis and having multiple comorbidities were significant predictors of higher OOP costs. Overall high scores on the COST-FACIT indicated low levels of financial burden for the entire sample.Conclusion Largely attributable to being managed with active surveillance, Australian men diagnosed with localised prostate cancer reported relatively low OOP costs and financial burden in the first 6 months post-diagnosis. Together with clinical outcomes, clinicians can use this up to date evidence on costs and perceived financial burdens to assist localised prostate cancer patients and their families make informed decisions about their preferred management option.
dc.identifier.citationLindsay D et al. (2024) The impact of management option on out-of- pocket costs and perceived financial burden among men with localised prostate cancer in Australia within 6 months of diagnosis. Australian Health Review 48(2), 172–181. doi:10.1071/AH23231
dc.identifier.otherdoi:10.1071/AH23231
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/11717
dc.language.isoen
dc.publisherAustralian Health Review
dc.titleThe impact of management option on out-of-pocket costs and perceived financial burden among men with localised prostate cancer in Australia within 6 months of diagnosis
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
The impact of management option on out-of-pocket costs and.pdf
Size:
728.29 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Agricultural and Veterinary Sciences